<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Curium on Bioecon</title><link>https://en.bioecon.ru/companies/curium/</link><description>Recent content in Curium on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Fri, 03 Jul 2026 21:22:07 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/companies/curium/index.xml" rel="self" type="application/rss+xml"/><item><title>Radiopharmaceuticals &amp; theranostics</title><link>https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/</link><pubDate>Fri, 03 Jul 2026 00:00:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/</guid><description>Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — &amp;lsquo;see what you treat, treat what you see&amp;rsquo; — now commercial at multi-hundred-million-dollar manufacturing scale.</description></item></channel></rss>